NYSE:BHVN Biohaven Q1 2025 Earnings Report $15.89 +0.50 (+3.24%) Closing price 03:59 PM EasternExtended Trading$16.10 +0.21 (+1.33%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Biohaven EPS ResultsActual EPS-$1.94Consensus EPS -$1.94Beat/MissMet ExpectationsOne Year Ago EPSN/ABiohaven Revenue ResultsActual RevenueN/AExpected Revenue$0.41 millionBeat/MissN/AYoY Revenue GrowthN/ABiohaven Announcement DetailsQuarterQ1 2025Date8/11/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsBiohaven's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Monday, November 10, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Biohaven Earnings HeadlinesBiohaven Ltd. Investors: Please contact the Portnoy Law Firm to recover your losses.September 2 at 4:12 PM | globenewswire.comInvestors in Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights – BHVNSeptember 2 at 3:53 PM | globenewswire.comThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history gives him 90% historical confidence that stocks will end 2025 up. However, he also has bad news: the same data also tells him the REAL market crash will likely arrive in 2026.September 2 at 2:00 AM | Chaikin Analytics (Ad)Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitSeptember 2 at 12:00 PM | prnewswire.comINVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of September 12, 2025 Lead Plaintiff Deadline in the Biohaven Ltd. (BHVN) Class Action – Investors With Significant Losses Encouraged to Contact the FirmSeptember 2 at 11:30 AM | globenewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Biohaven Ltd. (BHVN) Investors of September 12, 2025 DeadlineSeptember 2 at 10:25 AM | theglobeandmail.comSee More Biohaven Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Biohaven? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biohaven and other key companies, straight to your email. Email Address About BiohavenBiohaven (NYSE:BHVN) (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships. The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine. Its lead product, rimegepant—commercially marketed under the name NURTEC® ODT—has been approved for both acute migraine relief and migraine prevention in adults. Biohaven’s pipeline also includes atogepant, a once-daily oral CGRP receptor antagonist in late-stage development for migraine prevention, as well as earlier-stage candidates targeting N-methyl-D-aspartate (NMDA) receptors for chronic pain and other neurological disorders. In addition to its internal programs, Biohaven has established global licensing agreements and co-development partnerships to expand the reach of its migraine therapies in key markets such as Europe, Canada and Asia. The company leverages a hybrid model of in-house development and external collaborations to accelerate clinical progress and broaden patient access. Under the leadership of Founder and Chief Executive Officer Dr. Vlad Coric, Biohaven has built a multidisciplinary management team with deep experience in neuroscience drug development and commercial operations. Together, they aim to advance the company’s portfolio through late-stage clinical trials and regulatory submissions, with the goal of delivering novel treatments that improve patient outcomes in neurological and central nervous system disorders.Written by Jeffrey Neal JohnsonView Biohaven ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles What to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Upcoming Earnings Salesforce (9/3/2025)Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
